about
Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014.Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea.Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea.Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea.Cost-effectiveness of pneumococcal vaccination strategies for the elderly in KoreaInterim estimates of the effectiveness of the influenza vaccine against A(H3N2) influenza in adults in South Korea, 2016-2017 seasonPhysician Attitudes toward the Herpes Zoster Vaccination in South Korea.Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study.Disease burden of 2013-2014 seasonal influenza in adults in Korea.Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.Perception and Attitudes of Korean Obstetricians about Maternal Influenza VaccinationHerpes zoster vaccine in Korea.Perceptions of Tetanus-diphteria-acellular pertussis (Tdap) Vaccination among Korean Women of Childbearing Age.Perceptions of influenza vaccination during pregnancy in Korean women of childbearing age.Age- and influenza activity-stratified case definitions of influenza-like illness: experience from hospital-based influenza surveillance in South Korea.Analysis of Risk Factors for Severe Acute Respiratory Infection and Pneumonia and among Adult Patients with Acute Respiratory Illness during 2011-2014 Influenza Seasons in Korea.Severe influenza treatment guideline.Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly.Guideline on the prevention and control of seasonal influenza in healthcare setting.Simultaneous chylothorax and chylous ascites due to tuberculosis.Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.Liver abscess and empyema due to Lactococcus lactis cremoris.Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial.Current status of indwelling urinary catheter utilization and catheter-associated urinary tract infection throughout hospital wards in Korea: A multicenter prospective observational study.Hospital-based Influenza Morbidity and Mortality (HIMM) Surveillance for A/H7N9 Influenza Virus Infection in Returning Travelers.Safety and Effectiveness of Peramivir in Korean Adult Influenza Patients: Prospective Observational Study Based on Post-Marketing Surveillance DataSeroprevalence of Pertussis in Healthcare Workers without Adult Pertussis Vaccine Use at a University Hospital in KoreaFulminant amebic colitis mimicking pseudomembranous colitisThe National Influenza Surveillance System of KoreaSafety and Effectiveness Analysis of Kivexa® (lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients
P50
Q26821898-E0E58382-FC89-41FC-AF65-515BA54989F2Q30395949-A8E72051-6365-4467-AB97-2889B0AF8D16Q30398065-D463E70A-FB63-4E4B-BA9F-4FE84F43060CQ33434003-48D3EFCB-64A5-4D0C-8216-A49502F14455Q33675229-758BBEB0-1FAA-4D06-B1CF-7DA753ED2A2EQ33728468-172D28B0-4762-4DD8-B4CE-17F15595454AQ33728468-85259549-7041-40B3-B0B1-FCC7C043EC1DQ34303953-89923FD4-CA56-4D45-BC84-AE7814F1B5C0Q34704745-B9EE29AD-3407-4E8F-802D-635974EC9D8AQ36302217-E378F08B-621D-4E0F-B6CD-6B18E5816945Q36461527-93ECCF92-EDE7-416D-AD0C-D24590FA81D3Q36989767-B3CD39BB-67BC-4BA4-96F9-BB64D2D8AD5EQ37011022-F3CA07C0-285B-4F4B-806B-00C19489958AQ37192182-C1BFE6F8-EB98-456F-BDC9-D817CCE012FFQ37197126-7A2BBA35-2993-44F9-A4B6-66080F3DD0C9Q37514135-FBE1E52A-0FAE-4CBC-9245-69799ED8CAC5Q37547829-04EE5407-4299-49EC-A84E-F63BF89915ECQ37598807-BF36A411-2144-435C-8154-F00D8B8E0D8DQ37625249-35E17225-4ECB-4501-9241-75A38B501642Q37642238-5258EA8C-89E8-453A-9AD0-3685A3F86D50Q38563980-7D6C7E5D-D7B6-4B4D-BA72-D3E447FAD641Q40244064-82D9F56A-077F-4158-AD1B-C24FBD70FECCQ40344041-CFB0896B-16C6-4EA4-BC78-8BE19372BCD8Q40471889-D1AE90ED-0AA9-4BE6-A2E0-6CF821C1D368Q41029266-653865DD-1779-4CC2-A6C6-0112B5854C16Q41989599-3C1AF54F-2A8C-4F15-BEC6-8ED6B35DF688Q47550009-52A1A83C-FE27-46EB-B838-FF32646A361CQ56890304-9B80A368-F12F-4129-8AD6-992486CAEDEFQ59796024-7EA83041-4760-4318-8B47-D26EB5151279Q84799331-95849CAA-8C76-436F-B191-0148145C0E7DQ91599874-DCCB9D69-E431-4073-936E-036A6757FAD7Q91599936-3C4EBFC2-F9DD-4275-BB57-15AB6113F291
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Won Suk Choi
@ast
Won Suk Choi
@en
Won Suk Choi
@es
Won Suk Choi
@nl
Won Suk Choi
@sl
type
label
Won Suk Choi
@ast
Won Suk Choi
@en
Won Suk Choi
@es
Won Suk Choi
@nl
Won Suk Choi
@sl
prefLabel
Won Suk Choi
@ast
Won Suk Choi
@en
Won Suk Choi
@es
Won Suk Choi
@nl
Won Suk Choi
@sl
P106
P1153
56718971800
P31
P496
0000-0001-5874-4764